177 related articles for article (PubMed ID: 2514814)
1. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
3. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
4. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
5. The antitumor potency of progesterone antagonists is due to their differentiation potential.
Michna H; Gehring S; Kühnel W; Nishino Y; Schneider MR
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):203-10. PubMed ID: 1525061
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models.
Schneider MR; Michna H; Nishino Y; el Etreby MF
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):783-7. PubMed ID: 2285591
[TBL] [Abstract][Full Text] [Related]
8. Progesterone antagonists: tumor-inhibiting potential and mechanism of action.
Michna H; Nishino Y; Neef G; McGuire WL; Schneider MR
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):339-48. PubMed ID: 1562510
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibitory activity of a new antiestrogen, RU 16 117, on the development and growth of DMBA-induced rat mammary adenocarcinoma.
Labrie F; Kelly PA; Asselin J; Raynaud JP
Recent Results Cancer Res; 1976; (57):109-20. PubMed ID: 827798
[TBL] [Abstract][Full Text] [Related]
12. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
13. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats.
Luo S; Stojanovic M; Labrie C; Labrie F
Int J Cancer; 1997 Nov; 73(4):580-6. PubMed ID: 9389575
[TBL] [Abstract][Full Text] [Related]
15. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.
Zaccheo T; Giudici D; Di Salle E
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):677-80. PubMed ID: 8476783
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors.
von Angerer E; Prekajac J; Berger M
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):531-7. PubMed ID: 3924626
[TBL] [Abstract][Full Text] [Related]
18. Human chorionic gonadotropin inhibits N-Methyl-N-nitrosourea-induced mammary carcinoma growth in female Lewis rats.
Yuri T; Lai YC; Yoshizawa K; Tsubura A
In Vivo; 2012; 26(3):361-7. PubMed ID: 22523287
[TBL] [Abstract][Full Text] [Related]
19. Endocrine and antitumoral effects of R76713 in rats.
De Coster R; Van Ginckel R; Wouters W; Goeminne N; Vanherck W; Byloos M
J Enzyme Inhib; 1990; 4(2):159-67. PubMed ID: 2098522
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
